Back A A A Font Size Receive E-mail Alerts Press Releases

CIT 2018: MicroPort® Hosts Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®"

[2018-05-17] 

Suzhou, China – From March 22 to March 25, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 16th China Interventional Therapeutics ("CIT 2018") and hosted Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®", which attracted wide attention from the audience.
 
The FUTURE-I research is the First-In-Man ("FIM") study on Firesorb® Bioresorbable Sirolimus Target Eluting Coronary Scaffold System ("Firesorb®"). The study was a prospective single center study included 45 single coronary artery lesions of the subjects. All subjects received angiography and IVUS examination before coronary stents implantation, and underwent angiography, IVUS and OCT after operation, followed by two years of follow-up. The patients were divided into two cohorts, respectively received angiography, IVUS and OCT check again in six months and two years after operation (cohort 1) and one year, three years after operation (cohort 2). The main endpoint of the study is Target Lesion Failure. According to the result, the occurrence of the main endpoint in two years is zero, the occurrence of patient-oriented composite endpoint ("PoCE"), including death, myocardial infarction, and revascularization is 2.2%, and the occurrence of all-cause mortality, target vessel MI and stent thrombosis are all zero. Based on the two-year follow-up outcome, Firesorb® is one of the safe and effective solutions for patients with single-vessel coronary diseases.
 
During the session of bioabsorbable stent, Dr. Qiyi Luo introduced the design features of Firesorb®. Firesorb® bioabsorbable stent with polymer degradation in vivo poly-L-lactic acid ("PLLA") as the matrix material, poly D, L- lactide ("PDLLA") for drug balloon dilatation eluting stent of surface materials thickness is only 100-125μm, with low dose of Sirolimus as eluting drug, which is more light and with less degradation time. In the Innovation Summit, Dr. Qiyi Luo introduced the new products and new technologies under research to demonstrate MicroPort® is an innovative, high-tech medical device group.
 
On March 24, MicroPort® hosted Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®" chaired by Academician Runlin Gao of Fuwai Hospital of Chinese Academy of Medical Sciences, Dr. Alexandra Lansky of Yale University, Dr. Alfredo E. Rodriguez of Otamendi Hospital, Professor Zuyi Yuan of the First Affiliated Hospital of Xi'an Jiaotong University, and Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences.
 
Professor Andreas Baumbach released the three-month OCT result of Target AC Trial which shows the early healing effect of Firehawk® stents is non-inferior to that of the control group Xience stents. Afterwards, Professor Ankur Gupta and Professor Richard Anderson reviewed clinical cases of Firehawk®, which shows its excellent crossability and dilation ability. Professor Qi Zhang of East Hospital of Tongji University analyzed a case of Firehawk® treating left main disease under the guidance of intracavity imaging and physiological function examination, which further demonstrated the excellent performance of Firehawk®.
 
This conference fully demonstrated the excellent performance of Firehawk® and verified the safety and efficacy of Firehawk® and Firesorb® with evidence based medicine.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:Foreign Experts Visit MicroPort® During CIT 2018
[Next]:MicroPort® Attends CIT 2018